IV期非小细胞肺癌中对克唑替尼的重排及反应
rearrangement and response to crizotinib in Stage IV non-small cell lung cancer.
作者信息
Suryavanshi Moushumi, Panigrahi Manoj Kumar, Kumar Dushyant, Verma Haristuti, Saifi Mumtaz, Dabas Bharti, Batra Ullas, Doval Dinesh, Mehta Anurag
机构信息
Centre for Molecular Diagnostics and Cell Biology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
出版信息
Lung India. 2017 Sep-Oct;34(5):411-414. doi: 10.4103/lungindia.lungindia_116_17.
BACKGROUND
The frequency of ROS1 rearrangement in non-small cell lung cancers has been reported from 1.6% to 2.3%.
MATERIALS AND METHODS
We examined 105 lung adenocarcinoma patients for ROS1 rearrangement which were negative for EGFR and anaplastic lymphoma kinase. Clinical characteristics of ROS1 rearranged patients and their responses to crizotinib therapy were studied.
RESULTS
Of the 105 patients, three cases were positive for ROS1 rearrangement by fluorescence in situ hybridization analysis. All of them showed heterogeneous pattern. All the 3 ROS1-positive patients were females in their forties and started on crizotinib. All of them responded to treatment. One of them developed resistance after 3 months. Another one showed marked systemic response but central nervous system lesions progressed. The third case is doing well till date with inactive lesions on positron emission tomography scan.
CONCLUSIONS
The frequency of ROS1 rearrangement is low in non-small cell lung carcinoma, but their diagnosis offers patients an opportunity to receive highly effective targeted therapies.
背景
非小细胞肺癌中ROS1重排的频率报道为1.6%至2.3%。
材料与方法
我们检测了105例表皮生长因子受体（EGFR）和间变性淋巴瘤激酶均为阴性的肺腺癌患者的ROS1重排情况。研究了ROS1重排患者的临床特征及其对克唑替尼治疗的反应。
结果
在105例患者中，通过荧光原位杂交分析，3例ROS1重排呈阳性。所有病例均表现为异质性模式。3例ROS1阳性患者均为40多岁的女性，开始接受克唑替尼治疗。所有患者对治疗均有反应。其中1例在3个月后出现耐药。另一例表现出明显的全身反应，但中枢神经系统病变进展。第三例至今情况良好，正电子发射断层扫描显示病灶无活性。
结论
非小细胞肺癌中ROS1重排的频率较低，但其诊断为患者提供了接受高效靶向治疗的机会。
Zotero 插件